ClinicalTrials.Veeva

Menu

Influence of TyG Index and TG/HDL-C Ratio on Fetal Macrosomia

A

Ankara Etlik City Hospital

Status

Completed

Conditions

Fetal Macrosomatia
Hyperlipidemias
Lipid Metabolism Disorders

Treatments

Other: TyG index

Study type

Observational

Funder types

Other

Identifiers

NCT06463990
AECH-FIRATLIGIL-001

Details and patient eligibility

About

Metabolic disorders that can occur during pregnancy, in particular disorders of lipid metabolism and insulin resistance, can have a detrimental effect on pregnancy and the fetus.

The triglyceride level and other lipids increase slightly during pregnancy. This increase has a positive effect on the development of the fetus. However, an excessive increase in lipid levels can cause some metabolic disorders such as gestational diabetes and increase feto-maternal morbidity/mortality.

While some existing studies have shown that elevated triglyceride levels can cause fetal macrosomia, others have found no correlation between these two variables. The ratio of triglycerides to HDL is a widely used marker for lipid disorders. In addition, the triglyceride-glucose index is also an index used to detect insulin resistance.

Full description

In this study, the investigators aimed to investigate whether the ratio of triglycerides to high-density lipoprotein cholesterol and the triglyceride glucose index are associated with fetal macrosomia in low-risk nulliparous pregnant women.

Enrollment

302 patients

Sex

Female

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Screening for fetal macrosomia was based on the term defined according to the standards of the American College of Obstetricians and Gynecologists (ACOG).
  • Low-risk nulliparous singleton pregnant women.
  • Age between 18 and 40 years old

Exclusion criteria

  • Post-term pregnancies
  • Hospitalized for preterm labor or preterm premature rupture of membranes.
  • Gestational diabetes mellitus, diabetes mellitus type I - type II.
  • Pregnant women with fetal growth restriction, hypertensive pregnancy disorders, familial hypercholesterolemia and hyperlipidemia.
  • Multiparous pregnant women
  • Multiple pregnancies
  • Pregnant women with chronic diseases.
  • Pregnant women with impaired liver function;
  • Pregnant women with body mass index <25 and >40 kg/m2.

Trial design

302 participants in 2 patient groups

Study group
Description:
women with macrosomic newborns
Treatment:
Other: TyG index
Control group
Description:
women with non-macrosomic newborns
Treatment:
Other: TyG index

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems